Glycos Biotechnologies to Present at the Next Generation Bio-Based Chemicals Summit

Share Article

Chief Science Officer to Explore Growing Shift in the Industry from Biofuel to Biochemical Production

Expanding from Fuels to Chemicals

Glycos Biotechnologies, Inc. (GlycosBio), an international biochemical company commercializing industrial biological processes to convert low-value feedstocks into high-value sustainable chemicals, today announced the Company will be presenting at the Next Generation Bio-Based Chemicals Summit taking place February 14 – 17th in San Diego, CA.

Paul Campbell, Chief Science Officer for GlycosBio, will participate in a panel with other leading biochemical companies to explore the growing shift in the industry from biofuel to biochemical production. Panelists will examine why companies may be choosing biochemicals over biofuels, the long-term sustainability and future of such a choice, and the potential synergies between these two strategies.

With more than 90 speakers confirmed, the 2nd Annual Next Generation Bio-Based Chemicals Summit is quickly becoming a growing tradition for key industry players, leading developers, government representatives, ground breaking researchers, and renowned financiers to gather, discuss and foster cutting edge innovations for bio-based chemicals.

What:    “Expanding from Fuels to Chemicals”

Who:     Moderator
        John Eustermann, Partner, Stoel Rivers, LLP

        Alan Berry, Director, Microbial Physiology and HTS, Novozymes, Inc.
        Doug Cameron, Managing Director, Alberti Advisors, LLC
        Paul Campbell, PhD., Chief Science Officer, Glycos Biotechnologies
        Vonnie Estes, Vice President, Corporate Development, Codexis, Inc.
        Joseph Kocal, Director of Renewable Research, UOP, a Division of Honeywell, Inc.

Where:     Hilton San Diego Resort & Spa

When:     Wednesday, February 16th, 10:30am – 11:30am

For more information about the Next Generation Bio-Based Chemicals Summit, visit

About Glycos Biotechnologies, Inc.
Glycos Biotechnologies, Inc. (“GlycosBio”) is an international biochemical company commercializing advanced metabolic engineering and microbial strain processes that convert multiple low value feedstocks into a range of high value sustainable chemicals. By designing a portfolio of differentiated microorganisms, GlycosBio’s bioconversion technology produces a diverse set of chemicals, including substitutes for fossil fuel derived petrochemicals, meeting the growing global demand for clean, environmentally safe biochemicals.

GlycosBio is privately held and focused on biochemical commercialization and production with established global partnerships including relationships with petrochemical companies to secure low cost, non-petroleum based chemicals. For more information, visit


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Suzanne Tormollen
Visit website